Acquista Criptovalute
Paga con
USD
USD
Buy & Sell
Hot
Supports Visa, Mastercard, SEPA & more
P2P
0 Fees
Flexible trading, zero fees
Gate Card
Use your crypto for payments worldwide
Mercati
Trading
Basic
Advanced
Futures
Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Opzioni
Hot
Trade European-style Vanilla Options
Conto unificato
Massimizza l'efficienza del tuo capitale
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Guadagna
Lancia
CandyDrop
Raccogli le caramelle per guadagnare airdrop
Launchpool
Staking rapido, guadagna potenziali nuovi token
HODLer Airdrop
Fai holding GT e ottieni enormi airdrop gratuitamente
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Investimento
Square
Square
Post, share, and explore crypto trends
Live
moments live
Live crypto market analysis
Chat
Chat with crypto traders
News
What is happening in crypto
flower_head
Altro
Promozioni
AI
Altro
TradFi
WCTC S8
Rewards
VTRS

Prezzo Viatris Inc

Closed
VTRS
$14,60
-$0,48(-3,18%)

*Data last updated: 2026-05-04 03:39 (UTC+8)

As of 2026-05-04 03:39, Viatris Inc (VTRS) is priced at $14,60, with a total market cap of $17,51B, a P/E ratio of -4,14, and a dividend yield of 3,19%. Today, the stock price fluctuated between $14,52 and $15,10. The current price is 0,55% above the day's low and 3,31% below the day's high, with a trading volume of 7,36M. Over the past 52 weeks, VTRS has traded between $14,52 to $15,20, and the current price is -3,94% away from the 52-week high.

VTRS Key Stats

Yesterday's Close$14,94
Market Cap$17,51B
Volume7,36M
P/E Ratio-4,14
Dividend Yield (TTM)3,19%
Dividend Amount$0,12
Diluted EPS (TTM)3,05
Net Income (FY)-$3,51B
Revenue (FY)$14,29B
Earnings Date2026-05-07
EPS Estimate0,52
Revenue Estimate$3,35B
Shares Outstanding1,17B
Beta (1Y)0.822
Ex-Dividend Date2026-03-09
Dividend Payment Date2026-03-18

About VTRS

Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as offers biosimilars franchises, including Fulphila, Ogivri, Hulio, and SEMGLEE. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
CEOScott Andrew Smith
HeadquartersCanonsburg,PA,US
Official Websitehttps://www.viatris.com
Employees (FY)30,00K
Average Revenue (1Y)$476,66K
Net Income per Employee-$117,16K

Viatris Inc (VTRS) FAQ

What's the stock price of Viatris Inc (VTRS) today?

x
Viatris Inc (VTRS) is currently trading at $14,60, with a 24h change of -3,18%. The 52-week trading range is $14,52–$15,20.

What are the 52-week high and low prices for Viatris Inc (VTRS)?

x

What is the price-to-earnings (P/E) ratio of Viatris Inc (VTRS)? What does it indicate?

x

What is the market cap of Viatris Inc (VTRS)?

x

What is the most recent quarterly earnings per share (EPS) for Viatris Inc (VTRS)?

x

Should you buy or sell Viatris Inc (VTRS) now?

x

What factors can affect the stock price of Viatris Inc (VTRS)?

x

How to buy Viatris Inc (VTRS) stock?

x

Risk Warning

The stock market involves a high level of risk and price volatility. The value of your investment may increase or decrease, and you may not recover the full amount invested. Past performance is not a reliable indicator of future results. Before making any investment decisions, you should carefully assess your investment experience, financial situation, investment objectives, and risk tolerance, and conduct your own research. Where appropriate, consult an independent financial adviser.

Disclaimer

The content on this page is provided for informational purposes only and does not constitute investment advice, financial advice, or trading recommendations. Gate shall not be held liable for any loss or damage resulting from such financial decisions. Further, take note that Gate may not be able to provide full service in certain markets and jurisdictions, including but not limited to the United States of America, Canada, Iran, and Cuba. For more information on Restricted Locations, please refer to the User Agreement.

Other Trading Markets

VTRS
CFD
Fai trading

Hot Posts su Viatris Inc (VTRS)

MidnightSeller

MidnightSeller

2025-12-26 04:25
Viatris Secures Multiple FDA and PMDA Approvals for Long-Acting and Hormonal Treatment Pipeline Healthcare company Viatris Inc. (VTRS) revealed significant regulatory progress across its pharmaceutical portfolio, marking a productive quarter for the organization's global development initiatives. The company has achieved a series of approvals and acceptances from major regulatory bodies that span injectable generics, contraceptive solutions, and rare disease therapies. **Generic Injectable Formulation Approved** In a major win for its generic medications division, the FDA has greenlit Viatris' octreotide acetate injectable suspension, which serves as a bioequivalent alternative to the branded Sandostatin LAR Depot formulation. This long-acting injectable is designed to manage symptoms associated with rare endocrine disorders, particularly acromegaly. The approval represents the company's fourth injectable authorization from the FDA during the current year, alongside previous clearances for iron sucrose, paclitaxel, and liposomal amphotericin B formulations. **Weekly Transdermal Contraceptive Advancement** The regulatory pathway for Viatris' innovative hormonal contraceptive has progressed favorably, with the FDA accepting its New Drug Application for a weekly transdermal patch delivery system. The formulation contains 150 mcg of norelgestromin combined with 17.5 mcg of ethinyl estradiol, representing a low-dose hormonal approach. The agency has assigned a targeted review completion date of July 30, 2026. This non-invasive reversible contraceptive option targets women of childbearing age with a BMI below 30 kg/m² who seek convenient hormonal birth control alternatives to daily oral medications. **Rare Eye Disease Investigational Program** The FDA has issued clearance for Viatris' investigational new drug application covering MR-146, an adeno-associated virus gene therapy candidate utilizing an enriched tear film technology platform. This therapeutic approach specifically addresses neurotrophic keratopathy, a degenerative corneal condition affecting approximately 73,000 individuals in the United States. The disease progressively damages corneal tissue and can lead to sight-threatening complications. Clinical evaluation is anticipated to commence during the first half of 2026, with the Phase 1/2 trial designated as CORVITA. **Japanese Market Authorization for Sleep Disorder Treatment** The Japan Pharmaceuticals and Medical Devices Agency has accepted Viatris' regulatory submission for pitolisant in treating obstructive sleep apnea syndrome. The company expects to file its Japanese new drug application for narcolepsy indications by year-end. Supporting data from Phase 3 clinical studies conducted in Japanese patient populations demonstrated meaningful efficacy outcomes. Patients administered pitolisant showed statistically significant reductions in excessive daytime sleepiness measurements using the Epworth Sleepiness Scale compared to placebo recipients (p=0.007), despite concurrent CPAP therapy utilization. In pre-market trading activity, VTRS stock was quoted at $11.66, reflecting a 0.34% decline on the Nasdaq exchange.
0
0
0
0
ser_ngmi

ser_ngmi

2025-12-23 17:17
Healthcare company Viatris Inc. (VTRS) marked significant progress across its global product pipeline, securing multiple regulatory approvals and acceptances that span rare disease treatments to women's health solutions. ## Generic Injectable Medication Gets FDA Greenlight The company's octreotide acetate for injectable suspension—a generic version of the branded Sandostatin LAR Depot—has received FDA approval. This long-acting injectable represents Viatris' fourth injectable approval this year, joining approvals for iron sucrose, paclitaxel, and liposomal amphotericin B. The medication is designed to manage symptoms of acromegaly and other rare conditions affecting the endocrine system. ## Contraceptive Patch Advances in FDA Review Process A more significant milestone for women's health emerged when the FDA accepted Viatris' New Drug Application for a novel low-dose estrogen transdermal patch for contraception. The weekly patch delivers 150 mcg norelgestromin and 17.5 mcg ethinyl estradiol—a combination designed for women seeking noninvasive, reversible birth control options. The FDA assigned a target decision date of July 30, 2026. The patch is intended for women of childbearing age with a BMI below 30 kg/m² who are suitable candidates for hormone-based contraception. This represents a potential new choice in the contraceptive landscape for patients preferring convenient transdermal delivery over daily oral pills. ## Gene Therapy for Rare Eye Disease Enters Clinical Development The investigational application for MR-146, an Enriched Tear Film adeno-associated virus gene therapy candidate, cleared FDA review barriers. This treatment targets neurotrophic keratopathy (NK), a progressive corneal disease affecting approximately 73,000 Americans. NK can gradually damage vision and pose sight-threatening risks. Viatris announced plans to initiate the CORVITA Phase 1/2 clinical trial during the first half of 2026, representing an important advancement for patients with limited treatment options. ## Sleep Disorder Treatment Gains Japanese Regulatory Traction The Japan Pharmaceuticals and Medical Devices Agency accepted Viatris' new drug application for pitolisant to treat obstructive sleep apnea syndrome (OSAS). The submission comes backed by positive Phase 3 trial data in Japanese patients. In the 12-week study, patients on pitolisant showed meaningful reductions in daytime sleepiness—as measured by the Epworth Sleepiness Scale—compared to placebo, with statistical significance (p=0.007). The benefit emerged even in patients already receiving CPAP therapy but experiencing residual excessive daytime sleepiness. Viatris intends to file another application for pitolisant in narcolepsy treatment by year-end. ## Stock Performance Reflects Market Reaction In early trading, VTRS shares moved to $11.66 on Nasdaq, representing a slight 0.34% decline. The regulatory developments underscore Viatris' strategy of expanding across multiple therapeutic areas, from rare diseases to common health conditions affecting millions globally.
0
0
0
0
VitaliksTwin

VitaliksTwin

2025-12-23 15:51
Viatris Inc. (VTRS) delivered significant regulatory progress Thursday, with the FDA greenlighting its generic version of a key acromegaly treatment and clearing the pathway for a novel weekly contraceptive patch to reach the market. ## Generic Octreotide Joins 2025 Injectable Lineup The healthcare company achieved its fourth FDA approval for injectable medications this year with octreotide acetate for injectable suspension, positioning itself as a competitive player in the rare disease treatment space. The drug, a long-acting generic equivalent of Sandostatin LAR Depot, addresses symptoms associated with acromegaly and other rare conditions. This approval comes alongside three other injectable clearances: iron sucrose, paclitaxel, and liposomal amphotericin B, signaling strong momentum in Viatris' injectable portfolio. ## Weekly Contraceptive Patch on FDA's Review Docket More notably, the FDA has accepted Viatris' New Drug Application for a weekly contraceptive patch formulation, setting July 30, 2026 as the target review completion date. The product combines 150 mcg norelgestromin with 17.5 mcg ethinyl estradiol in a transdermal delivery system designed for women with BMI below 30 kg/m² seeking non-invasive reversible contraception options. The weekly dosing format represents an alternative to daily pill regimens and other conventional methods, potentially expanding choices for women who prefer extended-interval dosing. ## Gene Therapy and Sleep Disorder Programs Gain Traction Beyond these headline developments, Viatris secured investigational new drug clearance for MR-146, an AAV-based gene therapy targeting neurotrophic keratopathy (NK), a sight-threatening corneal degenerative disease affecting approximately 73,000 Americans. The company plans to initiate Phase 1/2 trials in the first half of 2026. Internationally, Japan's PMDA accepted Viatris' application for pitolisant in obstructive sleep apnea syndrome, with the company on track to file for narcolepsy indication by year-end. The Japanese trials demonstrated statistically significant improvements in daytime sleepiness (p=0.007) among CPAP-resistant patients on pitolisant, measured by the Epworth Sleepiness Scale—a meaningful result for a large underserved patient population. In premarket trading on Nasdaq, VTRS shares reflected modest weakness, declining 0.34% to $11.66, though the pipeline breadth suggests multiple near-term catalysts across contraception, gene therapy, and neurological indications.
0
0
0
0